Merck KGaA at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

Merck KGaA brings 2 presentations to EBF 2026 in Barcelona. Its program covers immunogenicity lessons from a long-marketed product and hybrid immunocapture LC–MS methods that measure total antibody and conjugated payload for ADCs.

Organization	EBF 2026 Attendance
Merck KGaA Darmstadt, Germany
merckgroup.com Pharma Science and technology group whose healthcare business develops medicines in oncology, neurology and fertility, alongside life science and electronics businesses.	Talk Wed Nov 18 10:20–10:40am Part of Session 11: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 1 Never Too Old to Be Questioned: What a 20-Year-Old Product Taught Us About Immunogenicity Expectations Immunogenicity Talk Thu Nov 19 11:50am–12:10pm Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions Hybrid Immunocapture (IC)/LC-MS methods for the simultaneous quantification of Total Antibody and Conjugated Payload across different species case studies. New modalities · LC–MS

Organization

EBF 2026 Attendance

Merck KGaA

Darmstadt, Germany

merckgroup.com

Pharma

Science and technology group whose healthcare business develops medicines in oncology, neurology and fertility, alongside life science and electronics businesses.

Talk

Wed Nov 18
10:20–10:40am

Part of Session 11: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 1

Never Too Old to Be Questioned: What a 20-Year-Old Product Taught Us About Immunogenicity Expectations

Immunogenicity

Talk

Thu Nov 19
11:50am–12:10pm

Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions

Hybrid Immunocapture (IC)/LC-MS methods for the simultaneous quantification of Total Antibody and Conjugated Payload across different species case studies.

New modalities · LC–MS